{
    "clinical_study": {
        "@rank": "93929", 
        "brief_summary": {
            "textblock": "This is a single agent, prospective, open-label, monocenter, phase II trial of sorafenib in\n      patients with recurrent and/or metastatic salivary gland carcinoma. This trial will be\n      conducted with the primary aim to determine the response rate (CR+PR) according to the\n      RECIST criteria. Response rate according to CHOI criteria, correlation between CHOI criteria\n      and outcome, disease Control Rate (DCR) and acute toxicity will be evaluated as secondary\n      objectives."
        }, 
        "brief_title": "Activity of Sorafenib in Salivary Gland Cancer", 
        "completion_date": {
            "#text": "January 2013", 
            "@type": "Anticipated"
        }, 
        "condition": "Salivary Gland Cancer", 
        "condition_browse": {
            "mesh_term": "Salivary Gland Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically proven relapsed and/or metastatic salivary gland cancer for which\n             potentially curative options such as surgery or radiotherapy are not indicated\n\n          -  One target lesion measurable by CT-scan or MRI according to RECIST criteria\n\n          -  Age + 18 years\n\n          -  ECOG 0 or 1\n\n          -  Adequate bone marrow, liver and renal function\n\n          -  Signed written informed consent\n\n        Exclusion Criteria:\n\n          -  Symptomatic metastatic brain or meningeal tumors\n\n          -  History of cardiac disease such as congestive heart failure>NYHA class 2\n\n          -  Active CAD\n\n          -  Cardiac arrhythmias requiring anti-arrhythmic therapy or uncontrolled hypertension\n\n          -  Pregnant or breast-feeding patient\n\n          -  Patients with evidence or history of bleeding diathesis\n\n          -  Patients undergoing renal dialysis\n\n          -  Patients unable to swallow oral medication"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "37", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 6, 2012", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01703455", 
            "org_study_id": "INT29/10"
        }, 
        "intervention": {
            "description": "400 mg twice daily, on a continuous basis (each morning and evening), in 4 week cycles", 
            "intervention_name": "Sorafenib", 
            "intervention_type": "Drug"
        }, 
        "intervention_browse": {
            "mesh_term": "Sorafenib"
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Salivary gland cancer metastatic disease recurrent disease clinical trial", 
        "lastchanged_date": "January 29, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Milano", 
                    "country": "Italy", 
                    "zip": "20133"
                }, 
                "name": "IRCCS Istituto Nazionale Tumori"
            }
        }, 
        "location_countries": {
            "country": "Italy"
        }, 
        "number_of_arms": "1", 
        "official_title": "Sorafenib in Recurrent and/or Metastatic Salivary Gland Carcinomas: Phase II Study", 
        "overall_status": "Active, not recruiting", 
        "oversight_info": {
            "authority": "Comitato Etico Indipendente:Fondazione IRCCS Istituto Nazionale Tumori", 
            "has_dmc": "Yes"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "October 2012", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "description": "Response Rate according to RECIST criteria. Response will be evaluated every 2 months.", 
            "measure": "Objective response", 
            "safety_issue": "No", 
            "time_frame": "8 weeks"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01703455"
        }, 
        "responsible_party": {
            "investigator_affiliation": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
            "investigator_full_name": "Lisa Licitra", 
            "investigator_title": "MD", 
            "responsible_party_type": "Principal Investigator"
        }, 
        "secondary_outcome": [
            {
                "description": "number of patients with adverse events", 
                "measure": "safety", 
                "safety_issue": "No", 
                "time_frame": "4 weeks"
            }, 
            {
                "measure": "response rate according to CHOI criteria", 
                "safety_issue": "No", 
                "time_frame": "8 weeks"
            }, 
            {
                "measure": "correlation between CHOI criteria and outcome", 
                "safety_issue": "No", 
                "time_frame": "one year"
            }
        ], 
        "source": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Fondazione IRCCS Istituto Nazionale dei Tumori, Milano", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "September 2010", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Diagnostic", 
        "study_type": "Interventional", 
        "verification_date": "January 2013"
    }
}